Consumer Trends

Blackstone Explores Sale of ZO Skin Health, Valuation Could Reach $2 Billion

By Intent.Health Team • September 08, 2026
blackstone exploremsale

What's Happening

Investment firm Blackstone is exploring a sale of ZO Skin Health, a medical-grade skincare company that could be valued at around $2 billion in a potential transaction, according to people familiar with the matter. The sale process is still in an early stage. (Reuters)

Blackstone is working with investment banks Citigroup and Raymond James on the potential sale. Blackstone and Citi declined to comment, while ZO Skin Health and Raymond James did not immediately respond to requests for comment. (Reuters)

The potential transaction comes at a time when buyers are showing strong interest in clinically backed skincare brands distributed through physicians and skincare professionals, rather than relying entirely on traditional over-the-counter retail channels. (Reuters)

ZO Skin Health Operates in the Medical-Grade Skincare Market

The brand was founded by dermatologist Zein Obagi

ZO Skin Health was founded in 2007 by dermatologist Dr. Zein Obagi.

The company's product range includes:

Unlike many mass-market skincare brands, ZO's products are distributed through physicians and skincare professionals. (Reuters)

That distribution model places the brand closer to the professional skincare and aesthetic-medicine market than conventional consumer beauty products sold primarily through supermarkets, drugstores or general beauty retailers.

Why Physician-Distributed Skincare Is Attracting Buyers

Clinical backing is becoming a competitive advantage

The potential sale comes as strategic buyers increasingly prioritize skincare companies with products supported by clinical positioning and professional distribution.

Reuters reported that buyers are interested in brands like ZO because of their perceived efficacy and steadier demand compared with over-the-counter products. (Reuters)

That reflects an important shift in the skincare market.

Consumers are becoming more interested in products positioned around dermatology, clinical evidence and professional recommendations. That can give physician-distributed brands a different commercial profile from products that compete primarily through mass retail advertising.

Doctors can influence the purchase decision

The physician-distribution model also gives skincare companies access to a different kind of consumer journey.

Instead of a shopper encountering a serum on a retail shelf and deciding independently whether to purchase it, the product can be recommended by a dermatologist or skincare professional as part of a treatment or skincare routine.

That can strengthen consumer confidence and potentially support repeat purchases.

ZO Fits Into a Broader Convergence of Healthcare and Beauty

Skincare is becoming more medicalized

The growth of medical-grade skincare reflects a broader convergence between healthcare, dermatology and beauty.

Consumers increasingly look for products that promise more than cosmetic benefits, including solutions aimed at specific skin conditions and concerns.

That has helped create a category in which dermatologists, aesthetic clinics and professional skincare providers play a major role in product discovery and recommendation.

ZO's model fits directly into that trend.

The Potential $2 Billion Valuation Is Significant

Blackstone is evaluating a sizable exit

A potential valuation of around $2 billion would make ZO Skin Health a significant transaction in the consumer-health and skincare market. (Reuters)

For Blackstone, a sale would represent a potential realization of value from its investment in the company.

For a buyer, the transaction would provide access to an established professional skincare platform with a physician-led distribution model.

The eventual price, however, could change substantially depending on buyer interest, financial performance and broader market conditions.

The Sale Is Still at an Early Stage

There is no confirmed transaction yet

The most important qualifier is that Blackstone is only exploring a sale.

The process is in its early stages, meaning the company may ultimately be sold, but there is no guarantee that a transaction will occur or that it will happen at the reported valuation. (Reuters)

Potential buyers may also conduct extensive due diligence on the company's growth, physician relationships, product economics and competitive position before deciding whether to make an offer.

Why Strategic Buyers May Be Interested

Professional distribution can provide steadier demand

Over-the-counter skincare brands often depend heavily on retail traffic, promotions and consumer advertising.

Physician-distributed brands can operate differently.

A recommendation from a dermatologist or skincare professional can create demand that is tied more closely to an individual's treatment or skincare needs.

That may produce more predictable repeat purchasing behavior, which is one reason Reuters said buyers are placing greater value on clinically backed, physician-distributed skincare businesses. (Reuters)

Professional channels can also support premium pricing

Medical-grade products are often positioned at a higher price point than mass-market skincare.

When consumers perceive a product as clinically supported and professionally recommended, they may be more willing to pay a premium.

That creates an attractive combination for potential buyers: specialized products, professional distribution and potentially stronger customer loyalty.

Blackstone's Role Highlights the Financialization of Skincare

Private-equity firms have increasingly invested in healthcare-adjacent consumer businesses, including medical aesthetics, dermatology and professional skincare.

These companies can sit at an attractive intersection of healthcare demand and consumer spending.

Unlike many traditional healthcare businesses, skincare can also benefit from consumers paying directly for products and services rather than depending entirely on insurance reimbursement.

That gives investors exposure to a market with recurring consumer demand and multiple potential growth channels.

The Professional Channel Is the Core Asset

For a potential buyer, ZO's value may extend beyond the products themselves.

Its network of physicians and skincare professionals can be a valuable commercial asset because those professionals influence which products patients and customers use.

A buyer could potentially use that channel to:

That makes the professional distribution network strategically important in determining the company's eventual valuation.

Digital Marketing Still Has a Role

A physician-led distribution strategy does not eliminate consumer marketing.

Digital advertising, education, social media and online research can still influence consumers before they visit a dermatologist or skincare professional.

This creates a hybrid commercial model:

Professional recommendation creates trust, while digital discovery creates awareness and demand.

Brands that can connect both sides effectively may be particularly attractive to buyers looking for growth.

The Potential Sale Signals Continued M&A Interest in Skincare

Buyers are looking for brands with defensible positioning

The reported interest in ZO is part of a broader M&A environment in which buyers are searching for consumer-health brands with strong differentiation.

A brand built around professional recommendation and clinical positioning can be harder to replicate than a conventional over-the-counter product competing mainly on packaging, price and advertising.

That can make it more attractive in an acquisition.

Why This Matters

The potential ZO Skin Health sale shows that medical-grade skincare is increasingly being viewed as a healthcare-related investment category rather than simply a beauty business.

The reported $2 billion valuation reflects investor interest in brands that combine clinical credibility, professional distribution and recurring consumer demand. (Reuters)

It also demonstrates the value buyers are placing on trusted distribution channels.

A skincare company that has established relationships with doctors and skincare professionals can have a different competitive position from one that depends entirely on retail shelves and advertising.

Looking Ahead

Blackstone's exploration of a sale is still at an early stage, so the eventual outcome remains uncertain. (Reuters)

The next important development will be whether potential buyers emerge with offers that support or exceed the roughly $2 billion valuation being discussed.

The broader market will also be watching whether other physician-led skincare and aesthetic-health businesses attract similar interest.

If buyers continue prioritizing clinically backed brands with professional distribution, more investment and consolidation could follow across dermatology, aesthetic medicine and medical-grade skincare.

Key Takeaways

What This Means for Healthcare Marketers

The biggest signal here is the value of professional influence.

ZO Skin Health is not building its position solely through mass consumer advertising. Its relationship with physicians and skincare professionals is part of the product's commercial advantage.

For healthcare marketers, that means the channel through which a product reaches the customer can be as valuable as the product itself. A trusted professional recommendation can become a powerful acquisition and retention mechanism, particularly in categories where consumers are making health-related decisions.

The broader lesson is that brands sitting between healthcare and consumer markets should track not only consumer demand, but also which professionals influence that demand and how those relationships shape purchasing behavior.